Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions she has had with NICE on developing its methodologies to ensure future access to (a) innovative one-time treatments and (b) cell and genetic therapies.

Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.

The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.